And platinum medicine at the 16th Protein Engineering Summit (PEGS) showcased innovative CCR8 antibodies.

Introduction: And Platinum Pharmaceuticals demonstrated its monoclonal antibody HBM1022 developed for CCR8 targets through oral presentation at the 16th Protein Engineering Summit (PEGS).
-- Cambridge, Massachusetts, Netherlands, and Suzhou, China, September 2, 2020 /AGENCY/ -- Global Innovative Biopharmaceuticals and Platinum Pharmaceuticals, which are in clinical development, today announced that they have presented their monoclonal antibody HBM1022 developed for CCR8 targets through oral presentation at the 16th Protein Engineering Summit (PEGS).
CCR8 is a challenging G protein coupled subject (GPCR), and research data show that the CCR8 antibody HBM1022, developed by Platinum Pharmaceuticals, has good anti-tumor function and cross-reacts with crab monkey CCR8.
16th PEGS Conference was held in Boston from August 31st to September 4th, 2020.
in a variety of solid tumors, CCR8 is specifically expressed on tumor-infused regulatory T-cells (Tregs), while in extrinsic blood Treg or normal tissue is largely unsealed.
studies have shown a clear correlation between the level of expression of CCR8 and the prognosticity of breast cancer patients.
these data show that CCR8 is a potential target for cancer treatment.
and Platinum Pharmaceuticals have successfully developed specific antibodies for CCR8 using its powerful antibody discovery platform, including monoclonal B-cell technology, phage display and hybrid tumors.
According to preclinical studies, HBM1022 shows significant anti-tumor effects and potentially good synergy with anti-PD-1 antibodies by removing Treg cells in the tumor micro-environment in combination with CCR8 specificity.
addition, HBM1022 also blocks the binding of CCR8 to its mating body CCL1, while inhibiting the function of TIL-Treg in CCL1-mediated tumor micro-environment.
"HBM1022 project through the study of CCR8 to achieve effective regulation of the tumor micro-environment, whether single or combined drug, have very good therapeutic potential.
we are very optimistic about the development prospects of HBM1022 and believe that the project will provide new treatment options for patients with multiple types of oncology. Dr. Jinsong Wang, Founder, Chairman and CEO of
and Platinum Pharmaceuticals, said, "The successful development of new antibodies for challenging targets such as GPCR has once again proven the powerful drug discovery capabilities of the platinum pharmaceutical antibody technology platform.
"